Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis
- 47 Downloads
Vulvovaginal candidiasis (VVC), caused by Candida albicans, affects women’s health and life. We aimed to explore the correlation between ERG3 as well as Efg1 mutation/overexpression and azoles-resistance, and the correlation between ERG3 and Efg1 mRNA expression in C. albicans. First, C. albicans was isolated from clinical VVC patients. ERG3 and Efg1 mutations were detected by polymerase chain reaction (PCR) and sequencing, and the expression levels of these two genes were also identified by qRT-PCR. Correlations between mutation/overexpression of ERG3/Efg1 and azoles-resistance as well as ERG3 and Efg1 mRNA expression were analyzed. Based on the ERG3 sequencing, the results showed that there were 2 missense mutation sites, 1 nonsense mutation site, and 4 silent mutation sites, while 1 missense mutation sites, 1 nonsense mutation site, and 12 silent mutation sites were found in Efg1. Furthermore, the mRNA levels of ERG3 gene in the strains sensitive to FCA, ITR or VRC were higher than those in the strains resistant to FCA, ITR, VRC (P < 0.05). While for the mRNA levels of Efg1, susceptible strains were lower than resistant strains. Besides, there was a significant linear negative correlation between ERG3 and Efg1 mRNA expression (r = − 0.614, P < 0.001).
KeywordsCandida albicans Azoles Drug resistance ERG3 Efg1
This work was supported by Basic Research Project supported by Shanxi Province, China (Program No. 201701D121171), Research and Development Key Projects of Shanxi Province (Program No. 201603D321063), Research Project Supported by Health and Family Planning Commission of Shanxi Province, China (Program No. 201601050). Meanwhile, the project was supported by the Science & Technology Innovation Foundation for Univerisities in Shanxi Province, China (Program No. 20161118).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no competing interests.
- 2.Gharaei A, Erahimzadeh A, Khorashad ARS, Jorjani O, Jamshidi A et al (2015) Determination of prevalancy and species of vulvovaginal candidiasis and clinical findings correlation. J Gorgan Univ Med Sci 17:109–113Google Scholar
- 4.Fan SR, Bai FY, Liao QP, Liu ZH, Li J et al (2008) Genotype distribution of Candida albicans strains associated with different conditions of vulvovaginal candidiasis, as revealed by microsatellite typing. Sex Transm Infect 84:103–106. https://doi.org/10.1136/sti.2007.025700 CrossRefPubMedGoogle Scholar
- 8.Sanglard D, Ischer F, Bille L (1998) Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241–253. https://doi.org/10.1097/00001813-199802000-00010 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Perea S, López-Ribot JL, Kirkpatrick WR, Mcatee RK, Santillán RA et al (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676–2684CrossRefGoogle Scholar
- 11.Strzelczyk JK, Slemp-Migiel A, Rother M, Gołąbek K, Wiczkowski A (2013) Nucleotide substitutions in the Candida albicans ERG11 gene of azole-susceptible and azole-resistant clinical isolates. Acta Biochim Polon 60:547. https://doi.org/10.1016/B978-0-12-420067-8.00023-4 CrossRefPubMedGoogle Scholar
- 14.Yang J, Feng W, Wang Y, Chen J, Xi Z et al (2016) Mutation and elevated expression of ERG5 gene in anti-fungal drugs of Candida albicans. China J Health Insp 4:542–545Google Scholar
- 16.Vale-Silva LA, Coste AT, Ischer F, Parker JE, Kelly SL et al (2012) Azole resistance by loss of function of the sterol Δ5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother 56:1960–1968. https://doi.org/10.1128/AAC.05720-11 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Lo HJ, Wang JS, Lin CY, Chen CG, Hsiao TY, Hsu CT, Su CL, Fann MJ, Ching YT, Yang YL (2005) Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans. Antimicrob Agents Chemother 49:1213–1215. https://doi.org/10.1128/AAC.49.3.1213-1215.2005 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Su H-c, Cheng B, Shi X-m (2010) The difference of EFG1 and HGC1 expression between the myceial and yeast from of Candida albicans. Chin J Dermatol Vener Dis 24:304–306Google Scholar
- 24.Florent M, Fabrice P, Claire L, Michel M, Patrice LP (2012) Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J Antimicrob Chemother 67:2131–2138. https://doi.org/10.1093/jac/dks186 CrossRefGoogle Scholar
- 25.Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 47:2404–2412. https://doi.org/10.1128/aac.47.8.2404-2412.2003 CrossRefPubMedPubMedCentralGoogle Scholar